Ideas
Partners
Consultants
Calls
EU Projects
Blog NEW
- Europe towards City Innovation Hubs
  
  Written by Matteo Satta EU funding has always helped cities support their innovation processes, particularly on digital transformation and environment, but the approach is now moving toward a new ambitious […]
- Mistakes that Cities Should Be Avoiding in EU Projects
  
  By Matteo Satta Nowadays, we are seeing an increasing trend of people requesting to lower taxes and, as a result, public budgets. This leads many cities to try to find […]
- How a city can boost your Smart City project
  
  By Matteo Satta The commission has been heavily investing in pilot Smart City projects for a long time, but you may often have R&D or innovation projects pretending to have […]
- How to involve a city in your project? Here are a few tips.
  
  Article written by Matteo Satta (Smart) City projects are more and more funded by the European Commission, but consortia often struggle to get cities on board or really engage them. […]
- >> See all posts
Log In Sign Up

Want to see this project on homepage?
Propose a Picture

Optimisation of treatment with off-patent antimicrobial agents of ventilator-associated pneumonia (VAP) (MagicBullet)
Start date: Jan 1, 2012, End date: Dec 31, 2015 PROJECT FINISHED

Background. Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrugresistant gram-negative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, and “old” drug, is now the antimicrobial with greatest in vitro activity against MDR-GNB. However, no randomized clinical trial with colistin has been carried out. Additional aspects of colistin are also not well known, such as the appearance of resistant strains or alterations in the intestinal microbiome during treatment. Furthermore, conventional microbiological techniques take 48 to 72 hours to identify pathogens and determine their susceptibility. This is too long if empiric treatment is inappropriate.Objetives. The overall goal is the optimisation of the treatment of VAP caused by MDR-GNB, by defining a gold standard empiric therapy and reducing the period of time needed for the determination of the etiology and susceptibility of pathogens.Methods. MagicBullet proposes a randomized, open label, multicenter, clinical trial to compare the safety and efficacy of colistin vs. meropenem, both combined with levofloxacin, for empirical treatment of VAP. The pharmacokinetic and pharmacodynamic characteristics of colistin will be determined. Evaluation of the impact of the both treatments in the intestinal microbiome of patients and in the Ventilator-associated pneumonia (VAP) is one of the most common and severe hospital-adquired infections, and multidrug-resistant gramnegative bacilli (MDR-GNB) constitute the main etiology in many countries. Inappropriate empiric antimicrobial treatment is associated with increased mortality. In this context, the empirical treatment of choice for VAP is unknown. Colistin, and “old” drug, is now the antimicrobial with greatest in vitro activity against MDR-GNB. However, no randomized clinical trial with colistin has been carried out. Additional aspects of colistin are also not well known, such as the appearance of resistant strains or alterations in the intestinal microbiome during treatment. Furthermore, conventional microbiological techniques take 48 to 72 hours to identify pathogens and determine their susceptibility. This is too long if empiric treatment is inappropriate.